Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q4 EPS of ($0.75), $0.04 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $10.28 million versus the consensus estimate of $13.12 million.

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.